NY-ULTIVUE
7.4.2022 16:02:08 CEST | Business Wire | Press release
Ultivue, an industry leader in multiplexing tools for tissue biomarker analysis, and Paige , the global leader in AI-based diagnostic software in pathology, today announced a partnership to collaborate on the co-development and co-marketing of AI-powered spatial immunophenotype capabilities to pharmaceutical and research customers.
Collaborative efforts will initially focus on the development of AI to enable improved understanding of the tumor microenvironment and support the interpretation of Ultivue’s novel multiplex immunofluorescence (mIF) immuno-oncology biomarker panels.
The Paige portfolio includes the Paige Platform, a comprehensive imaging solution composed of the FDA-cleared and CE-marked FullFocus™, an intuitive and responsive viewer for pathology scans that supports primary diagnosis together with a data management solution for storage of pathology scans. The fast, zero-footprint, scanner-agnostic viewer, storage capabilities and AI-based diagnostic software help pathologists review cases and support their overall workflow.
Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation, develops unique platform agnostic solutions for use in both mIF imaging and spatial phenomics. Its proprietary InSituPlex® technology, designed for fast and comprehensive exploration of biologically relevant targets, up to 12-plex, with same slide-H&E analysis in precious tissue samples combines the power of computational pathology & spatial biology to guide translational science in immuno-oncology.
“This collaboration with Paige is an exciting milestone for Ultivue as we consider the evolving impact of AI and deep learning tools on histopathological images in clinical settings,” said Jacques Corriveau, CEO, Ultivue. “Importantly, our aligned goals are to facilitate the decentralization and democratization of the generation and analysis of complex spatial data.”
“The combination of Ultivue’s robust biomarker detection capabilities and Paige’s AI-enabled computational pathology technology allows us to deliver new products that will elevate how immuno-oncology research is done today,” said David Klimstra, M.D., Founder and Chief Medical Officer at Paige. “By uniting two platform-agnostic technologies, we are well-positioned to enable broad adoption of our AI-powered biomarker imaging solutions.”
About Paige
Paige was founded in 2017 by Thomas Fuchs, Dr.Sc., David Klimstra, M.D., and colleagues from Memorial Sloan Kettering Cancer Center (MSK). The company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of AI-based technologies positioned to drive the future of diagnostics, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s products deliver insights to pathologists and oncologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA approval for an AI-based digital pathology product. For additional information, please visit: paige.ai , Twitter and LinkedIn .
About Ultivue
Ultivue provides researchers in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions and scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at ultivue.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005283/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting styrker rådgivning inden for bygningsaktiver gennem samarbejde med Grinity20.2.2026 23:18:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Grinity, et rådgivningsfirma med speciale i bygningsaktiver, der leverer tekniske, miljømæssige og bæredygtige udviklingstjenester til bygge- og ejendomsmarkederne. Med sæde i Tjekkiet og Slovakiet og mere end 130 specialister betjener Grinity private og offentlige kunder inden for kommerciel udvikling, industri, teknologi, bilindustri og bæredygtighed. Virksomheden tilbyder tværfaglig ekspertise inden for projekt- og omkostningsstyring, teknisk rådgivning, transaktionsydelser, ESG-rådgivning og energioptimering af bygninger. "Bæredygtighed er blevet en strategisk nødvendighed, men kunderne har også brug for en integreret ydelse på tværs af omfang, omkostninger, tidsplan, risiko og kvalitet," udtalte Pavel Čermák, administrerende direktør for Grinity. "Ved at kombinere vores ekspertise inden for projekt- og omkostningsstyring, teknisk rådgivning og energioptimering med Andersens globale platform kan vi levere omfattende, fremadsku
Telekom Srbija Group Announces Platinum Sponsorship of EXPO 2027 Belgrade20.2.2026 12:32:00 CET | Press release
Telekom Srbija to power EXPO 2027 and unveil dedicated pavilion showcasing its technology ecosystem Telekom Srbija Group today announced its Platinum Sponsorship of EXPO 2027 Belgrade, marking a major milestone in the company’s continued leadership in digital innovation and infrastructure across the region. As a Platinum Sponsor, Telekom Srbija will play a central role in delivering the digital backbone of EXPO 2027, powering connectivity and enabling the state-of-the-art technological infrastructure that will support one of the largest international events ever hosted in Serbia. EXPO 2027 represents a defining moment for Belgrade, Serbia, and the wider region. For Telekom Srbija, the partnership is both a strategic commitment and a landmark opportunity to demonstrate the full strength of its technological ecosystem on a global stage. Telekom Srbija will also host its own pavilion at EXPO 2027, creating an immersive space to showcase its technologies, innovation platforms and future-fa
Axelspace Secures Japan Ministry of Defense Satellite Constellation Project20.2.2026 12:01:00 CET | Press release
As an optical imagery provider, Axelspace has entered into a contract for the acquisition of image data Axelspace Corporation (“Axelspace”), a leading developer and operator of microsatellites dedicated to realizing its vision of “Space within Your Reach,” announced that, for the purpose of carrying out the Ministry of Defense’s satellite constellation project, it has entered into a contract with Tri-Sat Constellation Co., Ltd. and Mitsui Bussan Aerospace Co., Ltd. for acquisition of optical imagery data. Tri-Sat Constellation Co., Ltd. is a special purpose company (SPC) established by Mitsubishi Electric Corporation, SKY Perfect JSAT Corporation, and Mitsui & Co., Ltd. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260220758297/en/ An imagery of satellite constellation © the Ministry of Defense The Ministry of Defense’s satellite constellation project was awarded to a consortium comprising Mitsubishi Electric Corporation, S
Sai Life Sciences to Recruit 700+ Professionals in FY2720.2.2026 10:09:00 CET | Press release
Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract research, development and manufacturing organizations (CRDMOs), today announced plans to hire 700+ scientific, technical, and management professionals during 2026–27 as it scales capabilities to meet growing global demand for end-to-end drug discovery, development and manufacturing services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260220711675/en/ Integrated R&D Campus, Sai Life Sciences, Hyderabad, India The recruitment will span roles across medicinal chemistry, biology, DMPK, process and analytical development, formulation development, process engineering, technology transfer, quality, peptides, business development, program management, and manufacturing, among others. A specific area of focus through this recruitment drive will be on attracting high-calibre scientists from leading institutions in India and globally,
Balmain Beauty Introduces Destin de Balmain: A New Prestige Fragrance20.2.2026 08:30:00 CET | Press release
Balmain Beauty unveils Destin de Balmain, its debut prestige fragrance. The new feminine fragrance is a bold, floral fruity eau de parfum that captures the unstoppable energy of the Balmain woman: independent, youthful, and unapologetic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219851364/en/ Destin de Balmain (Photo Credit: Balmain Beauty) THE STORY: LIVE YOUR DESTINY Destin de Balmain is destiny you hold in your hands, a journey of optimism and infinite possibilities. The refillable fragrance unites those who express themselves without rules or expectations. Inspired by the Parisian House’s savoir-faire and modern pulse, the daring fragrance celebrates choosing your path and living your destiny. “Destin de Balmain features a joyful, optimistic spark of ripe strawberry,” said Quentin Bisch, Perfumer. “The fruit’s juicy vivacity brings bright, elevated sweetness to the composition. Notes of peony further convey the f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom